Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
4.21
USD
|
+0.72%
|
|
-7.27%
|
+29.94%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
782.3
|
128.6
|
220.7
|
330.6
|
-
|
-
|
Enterprise Value (EV)
1 |
531
|
-75.61
|
116
|
268.6
|
268.8
|
299.3
|
P/E ratio
|
-4.62
x
|
-0.73
x
|
-1.93
x
|
-2.68
x
|
-2.68
x
|
-3.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
397
x
|
71.9
x
|
8.09
x
|
EV / Revenue
|
-
|
-
|
-
|
322
x
|
58.4
x
|
7.33
x
|
EV / EBITDA
|
-7.94
x
|
0.63
x
|
-0.95
x
|
-1.9
x
|
-1.46
x
|
-1.48
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.81
x
|
0.55
x
|
1.71
x
|
3.76
x
|
6.9
x
|
15.6
x
|
Nbr of stocks (in thousands)
|
41,281
|
63,988
|
68,111
|
78,518
|
-
|
-
|
Reference price
2 |
18.95
|
2.010
|
3.240
|
4.210
|
4.210
|
4.210
|
Announcement Date
|
3/23/22
|
3/8/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
0.8333
|
4.6
|
40.85
|
EBITDA
1 |
-66.9
|
-119.2
|
-122.5
|
-141.7
|
-184.5
|
-202.2
|
EBIT
1 |
-72.81
|
-125.6
|
-131.2
|
-131.3
|
-151.5
|
-153.2
|
Operating Margin
|
-
|
-
|
-
|
-15,756.87%
|
-3,294.28%
|
-374.92%
|
Earnings before Tax (EBT)
1 |
-72.72
|
-123.7
|
-124.1
|
-117
|
-133.1
|
-131.7
|
Net income
1 |
-72.72
|
-123.7
|
-124.1
|
-126.7
|
-135.9
|
-128
|
Net margin
|
-
|
-
|
-
|
-15,206.56%
|
-2,955.32%
|
-313.33%
|
EPS
2 |
-4.100
|
-2.760
|
-1.680
|
-1.571
|
-1.570
|
-1.365
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
3/8/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.8333
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-28.62
|
-29.21
|
-32.43
|
-31.59
|
-35.1
|
-28.74
|
-29.26
|
-31.61
|
-34.9
|
-36.2
|
-33.4
|
-
|
-
|
EBIT
1 |
-26.16
|
-31.15
|
-28.62
|
-31.3
|
-34.55
|
-33.72
|
-35.1
|
-30.92
|
-31.45
|
-33.76
|
-28.12
|
-26.99
|
-26.78
|
-21.78
|
-22
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,214.09%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-26.15
|
-31.06
|
-28.4
|
-30.7
|
-33.52
|
-31.74
|
-33.27
|
-29.14
|
-29.94
|
-32.23
|
-30.05
|
-30.13
|
-29.65
|
-20.33
|
-20.54
|
Net income
1 |
-26.15
|
-31.06
|
-28.4
|
-30.7
|
-33.52
|
-31.74
|
-33.27
|
-29.14
|
-29.94
|
-32.23
|
-31.33
|
-31.39
|
-31.85
|
-20.33
|
-20.54
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,822.3%
|
-
|
-
|
EPS
2 |
-0.6300
|
-0.7500
|
-0.6900
|
-0.7400
|
-0.6100
|
-0.4300
|
-0.4500
|
-0.3900
|
-0.4000
|
-0.4000
|
-0.3929
|
-0.3857
|
-0.3929
|
-0.2500
|
-0.2500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
5/11/22
|
8/10/22
|
11/10/22
|
3/8/23
|
5/10/23
|
8/9/23
|
11/8/23
|
3/18/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
251
|
204
|
105
|
62
|
61.8
|
31.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-47.4%
|
-64.8%
|
-122%
|
-232%
|
-383%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
6.750
|
3.640
|
1.890
|
1.120
|
0.6100
|
0.2700
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
20.6
|
1.24
|
0.8
|
0.8
|
0.8
|
Capex / Sales
|
-
|
-
|
-
|
96%
|
17.39%
|
1.96%
|
Announcement Date
|
3/23/22
|
3/8/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
4.21
USD Average target price
19.29
USD Spread / Average Target +358.09% Consensus |
1st Jan change
|
Capi.
|
---|
| +29.94% | 331M | | +43.36% | 54.63B | | -5.31% | 39.92B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B | | -11.83% | 10.74B |
Other Biotechnology & Medical Research
|